TUESDAY, october 27 | 10:00AM ET

Vaccinex, Inc.

Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in
Non-Small Cell Lung Cancer, Huntington’s and Alzheimer’s disease and a recently announced collaboration with Merck for combination therapy with pepinemab and pembrolizumab in Head & Neck cancer. Vaccinex is based in Rochester, New York.

Featured Key Opinion Leader

Eric Siemers, MD
Former Distinguished Medical Fellow for Eli Lilly and Company's
Alzheimer's Disease Global Development Team

Eric Siemers, MD, has over 25 years of experience in clinical trials of neurodegenerative disease. His research focus is on the use of biomarkers in investigational drug research, the development of trial designs that fully characterize the effects of investigational drugs on chronic diseases, and more specifically, the development of strategies for treating individuals before the onset of symptoms of neurodegenerative diseases.

 

Dr. Siemers most recently served as a distinguished medical fellow for Eli Lilly and Company’s Alzheimer’s Disease Global Development Team, where he was responsible for the design and implementation of five large Phase III clinical studies, in addition to playing a major collaborative role in 2 public-private partnership studies.

 

Prior to his appointments at Lilly, Dr. Siemers founded and headed the Indiana University Movement Disorder Clinic; his research there included investigations of Parkinson’s and Huntington’s diseases, and he established one of the first centers for surgical Parkinson's treatments in the US.

 

Dr. Siemers served on the Board of Directors of the American Society of Experimental Neurotherapeutics, as founding member and Chair of the Alzheimer’s Association Research Roundtable, and Steering Committee member for the Alzheimer’s Disease Neuroimaging Initiative (ADNI). Dr. Siemers earned his medical degree with highest distinction from the Indiana University School of Medicine, where he completed an internship in the Department of Internal Medicine and residency in the Department of Neurology.

Management

Maurice Zauderer, Ph.D.
President and Chief Executive Officer

Maurice Zauderer, Ph.D. has served as our President and Chief Executive Officer and a member of our board of directors since our inception in April 2001. Prior to founding the company, Dr. Zauderer was an Associate Professor at the University of Rochester and has also held senior faculty positions at Columbia University. During his academic career, Dr. Zauderer held the position of visiting scientist at the Laboratory of Cell Biology, the Ontario Cancer Institute and the National Cancer Institute. Dr. Zauderer received a B.S. in Physics from Yeshiva University and a Ph.D. in Cell Biology from the Massachusetts Institute of Technology.

JTC_noText.png
Moderated by:
Jenene Thomas, CEO, JTC Team
© 2020 Virtual Investor. All rights reserved.
HeaderImage_10.22.20.png